Skip Navigation

European Journal of Heart Failure 2003 5(2):171-174; doi:10.1016/S1388-9842(02)00251-9
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chin, B. S.P.
Right arrow Articles by Lip, G. Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chin, B. S.P.
Right arrow Articles by Lip, G. Y.H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure

Bernard S.P. China, Nigel J. Langfordb, Sarah L. Nuttallb, Christopher R. Gibbsa, Andrew D. Blanna and Gregory Y.H. Lipa,*

a University of Birmingham, Division of Medical Sciences City Hospital, Birmingham, UK
b Queen Elizabeth Hospital Birmingham, UK

* Corresponding author. University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. Tel.: +44-121-5075080; fax: +44-121-554-4083 E-mail address: g.y.h.lip{at}bham.ac.uk


   Abstract

Background: Chronic elevation of plasma catecholamines and sympathetic stimulation in chronic heart failure (CHF) leads to increased production of free radicals, and so possibly to endothelial damage/dysfunction and atheroma formation. Abnormal oxidative stress may therefore be related to some of the high mortality and morbidity in CHF. The objective of the present prospective open study was to compare the effects of β-blockers and ACE inhibitors in relation to oxidative stress and endothelial damage in CHF.

Methods: We studied 66 outpatients with CHF: 46 patients were established on an ACE inhibitor and were then started on a β-blocker, and 20 patients not previously on ACE-inhibitors were started on lisinopril. Baseline levels of the measured parameters were compared to 22 healthy control subjects. Serum lipid hydroperoxides (LHP) and total antioxidant capacity (TAC) were determined as indices of oxidative damage and antioxidant defence, and plasma von Willebrand factor (vWf) as an index of endothelial damage/dysfunction.

Results: Baseline indices for the measures of oxidative damage and endothelial function in the 66 CHF patients were significantly higher than healthy control subjects [median LHP 7.5 (5.9–12.6) vs. 4.8 µmol/l, P=0.0022; TAC 428 (365–567) vs. 336 Trollox Eq. Units, P=0.0005; mean vWf 134±27 vs. 89±23 IU/dl, P<0.0001]. Following 3 months of maintenance therapy with β-blockers, there was significant reduction in LHP levels, but not TAC or vWf. ACE inhibitor therapy also significantly reduced vWf levels, but failed to have any statistically significant effects on LHP or TAC.

Conclusion: This pilot study suggests that oxidative stress in CHF may be due to increased free radical production or inefficient free radical clearance by scavengers. β-Blockers, but not ACE inhibitors, reduced lipid peroxidation in patients with CHF. No relation was demonstrated between a reduction in oxidative damage and endothelial damage/dysfunction.

Key Words: Beta-blockers • Congestive heart failure • ACE inhibitors • Oxidative stress • Endothelial damage/dysfunction

Received August 27, 2002; Revised October 9, 2002; Accepted December 2, 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. Y. Chong, G. J. Caine, B. Freestone, A. D. Blann, and G. Y. H. Lip
Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure
J. Am. Coll. Cardiol., February 4, 2004; 43(3): 423 - 428.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.